Treatment of behavioral/psychological symptoms in Alzheimer's disease

Myron F. Weiner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This review examines the evidence for the use of drugs as part of the treatment of depressive/psychotic symptoms and behavioral disturbances in persons with Alzheimer's disease. Although conventional antidepressants appear to relieve depressive symptoms in Alzheimer's disease patients, placebo seems equally effective. The use of most medications used to control psychotic symptoms and disturbed/disturbing behaviors in Alzheimer's disease is off-label and not strongly supported by randomized, placebo-controlled trials, especially for so-called agitation. For these reasons, trials of psychotropic drugs in Alzheimer's disease need a placebo condition in addition to active comparators and in the case of nondrug treatments, a sham treatment condition. Cholinesterase inhibiting drugs may reduce behavioral symptoms in addition to slowing cognitive decline. Selective (for brain region) GABA agonists seem to offer the greatest theoretical promise for reducing agitated behaviors not driven by depression or psychosis.

Original languageEnglish (US)
Pages (from-to)70-80
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume1
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Behavioral Symptoms
Alzheimer Disease
Placebos
Psychology
Depression
GABA Agonists
Psychotropic Drugs
Cholinesterases
Therapeutics
Pharmaceutical Preparations
Psychotic Disorders
Antidepressive Agents
Randomized Controlled Trials
Brain

Keywords

  • Alzheimer's disease
  • Behavior
  • Psychotropics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Treatment of behavioral/psychological symptoms in Alzheimer's disease. / Weiner, Myron F.

In: Expert Review of Neurotherapeutics, Vol. 1, No. 1, 2001, p. 70-80.

Research output: Contribution to journalArticle

@article{95c41c9104ba4b4f9110d8e762a01be4,
title = "Treatment of behavioral/psychological symptoms in Alzheimer's disease",
abstract = "This review examines the evidence for the use of drugs as part of the treatment of depressive/psychotic symptoms and behavioral disturbances in persons with Alzheimer's disease. Although conventional antidepressants appear to relieve depressive symptoms in Alzheimer's disease patients, placebo seems equally effective. The use of most medications used to control psychotic symptoms and disturbed/disturbing behaviors in Alzheimer's disease is off-label and not strongly supported by randomized, placebo-controlled trials, especially for so-called agitation. For these reasons, trials of psychotropic drugs in Alzheimer's disease need a placebo condition in addition to active comparators and in the case of nondrug treatments, a sham treatment condition. Cholinesterase inhibiting drugs may reduce behavioral symptoms in addition to slowing cognitive decline. Selective (for brain region) GABA agonists seem to offer the greatest theoretical promise for reducing agitated behaviors not driven by depression or psychosis.",
keywords = "Alzheimer's disease, Behavior, Psychotropics",
author = "Weiner, {Myron F.}",
year = "2001",
doi = "10.1586/14737175.1.1.70",
language = "English (US)",
volume = "1",
pages = "70--80",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Treatment of behavioral/psychological symptoms in Alzheimer's disease

AU - Weiner, Myron F.

PY - 2001

Y1 - 2001

N2 - This review examines the evidence for the use of drugs as part of the treatment of depressive/psychotic symptoms and behavioral disturbances in persons with Alzheimer's disease. Although conventional antidepressants appear to relieve depressive symptoms in Alzheimer's disease patients, placebo seems equally effective. The use of most medications used to control psychotic symptoms and disturbed/disturbing behaviors in Alzheimer's disease is off-label and not strongly supported by randomized, placebo-controlled trials, especially for so-called agitation. For these reasons, trials of psychotropic drugs in Alzheimer's disease need a placebo condition in addition to active comparators and in the case of nondrug treatments, a sham treatment condition. Cholinesterase inhibiting drugs may reduce behavioral symptoms in addition to slowing cognitive decline. Selective (for brain region) GABA agonists seem to offer the greatest theoretical promise for reducing agitated behaviors not driven by depression or psychosis.

AB - This review examines the evidence for the use of drugs as part of the treatment of depressive/psychotic symptoms and behavioral disturbances in persons with Alzheimer's disease. Although conventional antidepressants appear to relieve depressive symptoms in Alzheimer's disease patients, placebo seems equally effective. The use of most medications used to control psychotic symptoms and disturbed/disturbing behaviors in Alzheimer's disease is off-label and not strongly supported by randomized, placebo-controlled trials, especially for so-called agitation. For these reasons, trials of psychotropic drugs in Alzheimer's disease need a placebo condition in addition to active comparators and in the case of nondrug treatments, a sham treatment condition. Cholinesterase inhibiting drugs may reduce behavioral symptoms in addition to slowing cognitive decline. Selective (for brain region) GABA agonists seem to offer the greatest theoretical promise for reducing agitated behaviors not driven by depression or psychosis.

KW - Alzheimer's disease

KW - Behavior

KW - Psychotropics

UR - http://www.scopus.com/inward/record.url?scp=0035741579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035741579&partnerID=8YFLogxK

U2 - 10.1586/14737175.1.1.70

DO - 10.1586/14737175.1.1.70

M3 - Article

VL - 1

SP - 70

EP - 80

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -